Deloitte announced Atlas AI, the latest addition to its Quartz AI suite of cross-industry solutions built on the NVIDIA AI and NVIDIA Omniverse platforms.

As the first life sciences and health care (LSHC) offering under Quartz, Atlas AI includes a novel drug discovery accelerator that helps expedite research and bring new drugs to market faster. By using Generative AI models made accessible with BioNeMo, knowledge representation and reasoning, and custom protein Large Language Models (LLMs) and chemoinformatics LLMs, Atlas AI advances digital biology and transforms drug discovery with the latest AI technologies.

"Atlas AI is the very definition of how Generative AI and Large Language Models are enabling deeper data insights and more efficient human-machine collaboration to deliver real-world value," said Dan Ferrante, AI leader for innovation and R&D and managing director, Deloitte Consulting LLP. "Atlas brings together data, language models and AI-powered scientific pipelines in a no-code interface to save valuable research time. We are proud to team with NVIDIA to drive drug discovery innovation and deliver faster, easier and more accurate insights that can accelerate the time it takes to bring new drugs to market."

"Enterprises across industries are searching for new ways to empower transformation with Generative AI — including in health care and life sciences," said Kimberly Powell, vice president of health care at NVIDIA. "Built using NVIDIA BioNeMo, Atlas AI's offerings, including the new drug discovery accelerator, will help provide clients with the tools they need to innovate faster and more competitively, as well as the flexibility required to experiment with and build enterprise-grade applications."